HomeCompareIVRO vs GBDC

IVRO vs GBDC: Dividend Comparison 2026

IVRO yields 2247.19% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVRO wins by $29547769681.96M in total portfolio value
10 years
IVRO
IVRO
● Live price
2247.19%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29547769702.81M
Annual income
$27,169,407,696,231,896.00
Full IVRO calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — IVRO vs GBDC

📍 IVRO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVROGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVRO + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVRO pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVRO
Annual income on $10K today (after 15% tax)
$191,011.24/yr
After 10yr DRIP, annual income (after tax)
$23,093,996,541,797,110.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, IVRO beats the other by $23,093,996,527,813,988.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVRO + GBDC for your $10,000?

IVRO: 50%GBDC: 50%
100% GBDC50/50100% IVRO
Portfolio after 10yr
$14773884861.83M
Annual income
$13,584,703,856,341,314.00/yr
Blended yield
91.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

IVRO
No analyst data
Altman Z
5.8
Piotroski
5/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVRO buys
0
GBDC buys
0
No recent congressional trades found for IVRO or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVROGBDC
Forward yield2247.19%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$29547769702.81M$20.85M
Annual income after 10y$27,169,407,696,231,896.00$16,450,733.83
Total dividends collected$29380400700.81M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: IVRO vs GBDC ($10,000, DRIP)

YearIVRO PortfolioIVRO Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$235,419$224,719.10$12,492$1,791.70+$222.9KIVRO
2$5,196,120$4,944,221.38$16,527$3,160.58+$5.18MIVRO
3$107,548,439$101,988,590.74$23,588$5,904.90+$107.52MIVRO
4$2,087,920,928$1,972,844,098.40$37,141$11,901.65+$2087.88MIVRO
5$38,028,791,779$35,794,716,385.74$66,205$26,463.38+$38028.73MIVRO
6$649,994,244,523$609,303,437,319.89$137,452$66,612.65+$649994.11MIVRO
7$10,428,496,321,719$9,733,002,480,079.00$342,372$195,298.53+$10428495.98MIVRO
8$157,098,792,021,426$145,940,300,957,186.47$1,053,292$686,954.33+$157098790.97MIVRO
9$2,222,768,230,443,579$2,054,672,522,980,653.50$4,111,439$2,984,416.95+$2222768226.33MIVRO
10$29,547,769,702,806,524$27,169,407,696,231,896.00$20,849,974$16,450,733.83+$29547769681.96MIVRO

IVRO vs GBDC: Complete Analysis 2026

IVROStock

InVitro International develops test kits for non-animal testing in the United States and internationally. Its products include Irritection Assay System, an invitro test, which could be used to detect, rank, and predict the ocular and/or dermal irritation potential of cosmetics, consumer products, pharmaceuticals, and chemical raw materials; and Corrositex, an invitro test that determines chemical corrosivity. The company also provides customized technology services for Irritection Assay System installation and testing process, as well as independent testing laboratory services for irritancy and corrosivity testing requirements. Its products are principally used by the manufacturers of surfactants, petrochemicals, cosmetics, textiles, paper and pulp, pharmaceuticals, films and resins, solvents and cleaners, and other chemical raw materials. The company was founded in 1985 and is headquartered in Placentia, California.

Full IVRO Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this IVRO vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVRO vs SCHDIVRO vs JEPIIVRO vs OIVRO vs KOIVRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.